Analyzing CardioGenics (OTCMKTS:CGNH) and Beta Bionics (NASDAQ:BBNX)

Beta Bionics (NASDAQ:BBNX) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Beta Bionics and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
CardioGenics	N/A	N/A	N/A

Valuation and Earnings

This table compares Beta Bionics and CardioGenics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25 million	6.40	-$73.20 million	($1.51)	-9.53
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Beta Bionics.

Analyst Ratings

This is a breakdown of current ratings for Beta Bionics and CardioGenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	3	6	1	2.64
CardioGenics	0	0	0	0	0.00

Beta Bionics currently has a consensus price target of $19.70, suggesting a potential upside of 36.90%. Given Beta Bionics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Beta Bionics is more favorable than CardioGenics.

Summary

Beta Bionics beats CardioGenics on 5 of the 8 factors compared between the two stocks.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.